Related Experiment Video

Updated: Aug 6, 2026

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
07:18

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

Letter to the Editor Regarding "EXT2 promotes sarcoma progression and immune evasion via the AKT/c-Myc/PD-L1 axis: a

Qinghao Song1, Yiheng Liu2, Feifei Dou3

  • 1First Affiliated Hospital of Dalian Medical University, Dalian City, Liaoning Province, 116011, China.

Journal of Translational Medicine
|July 21, 2026
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
11:15

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

Published on: May 6, 2018

Establishment of Patient-Derived Xenograft Mouse Model with Human Osteosarcoma Tissues
02:35

Establishment of Patient-Derived Xenograft Mouse Model with Human Osteosarcoma Tissues

Published on: March 22, 2024

Related Experiment Videos

Last Updated: Aug 6, 2026

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
07:18

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
11:15

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

Published on: May 6, 2018

Establishment of Patient-Derived Xenograft Mouse Model with Human Osteosarcoma Tissues
02:35

Establishment of Patient-Derived Xenograft Mouse Model with Human Osteosarcoma Tissues

Published on: March 22, 2024

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Articles linked to this work by shared authors, journal, and citation graph.

Correction: Indobufen-based dual antiplatelet therapy in patients undergoing PCI: a systematic review and meta-analysis.

Frontiers in pharmacology·2026

Mutually beneficial interactions between bacteria and Arabidopsis promote phosphorus nutrition and growth.

Cell·2026

Indobufen-based dual antiplatelet therapy in patients undergoing PCI: a systematic review and meta-analysis.

Frontiers in pharmacology·2026

Palmitoylation in cardiovascular aging and disease: Mechanistic insights and therapeutic opportunities.

Ageing research reviews·2026

Robust [Formula: see text]-mapping in composites via joint beam-hardening and detector-response correction.

Scientific reports·2026

Exploring ChatGPT's potential in dialogic teaching: A comparative neurocognitive study of AI and human instruction.

Acta psychologica·2026

The role of IFNLR1 in modulating T cell infiltration and cancer progression in renal cell carcinoma.

Journal of translational medicine·2026

From equilibrium to dynamic metabolic imaging: the evolving role of magnetic resonance spectroscopic imaging in neurodegenerative disorders.

Journal of translational medicine·2026

Single-cell transcriptomics reveals transcriptional reprogramming and microenvironmental remodeling in ectopic ACTH/CRH-secreting pheochromocytomas.

Journal of translational medicine·2026

Canonical Wnt signaling in the regulation of prostate cancer stem cells: a key driver of castration-resistant prostate cancer and a therapeutic opportunity.

Journal of translational medicine·2026

Decoding the cholangiocarcinoma tumor microenvironment: from single-cell and spatial atlases to translational therapeutic targeting.

Journal of translational medicine·2026

Improved allocation strategies for red cell units of blood group O and RhD-negative revealed by current suboptimal utilization.

Journal of translational medicine·2026

Senomorphic miR-3155b suppresses the senescence-associated secretory phenotype in therapy-induced senescence.

Frontiers in cell and developmental biology·2026

Predictive biomarkers for precision treatment in rheumatoid arthritis: are we there yet?

Frontiers in pharmacology·2026

Breaking the ERK1/2 negative feedback loop: avoiding reactivation and acquisition of resistance by ERK1/2 to anti-cancer agents.

Frontiers in oncology·2026

Clinical trial landscape and translational priorities for adoptive T-cell and NK-cell therapies in gynecologic malignancies.

Frontiers in immunology·2026

Oncolytic reovirus: tumor-microenvironment remodeling, engineering constraints, and translational strategies.

Frontiers in immunology·2026

Profiling crystal engineered ligands for targeting treatment resistant androgen receptors.

Frontiers in pharmacology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us